Why the study?
Endothelial cyclooxygenase-1-derived prostanoids have cardioprotective roles but also suggested paradoxical pathological arterial activities, yet testing this was previously impossible without models separating vascular products from those generated elsewhere.
Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis, highlighting its potential as a therapeutic target.
Answers are grounded in this paper and cite their sources.
Endothelial COX-1 knockout model isolates vascular prostanoid effects; leaves open clinical relevance in human arteries.
Endothelial cyclooxygenase-1-derived prostanoids, including prostacyclin, have clear cardioprotective roles associated with their anti-thrombotic potential but have also been suggested to have paradoxical pathological activities within arteries. To date it has not been possible to test the importance of this because no models have been available that separate vascular cyclooxygenase-1 products from those generated elsewhere. Here, we have used unique endothelial-specific cyclooxygenase-1 knockout mice to show that endothelial cyclooxygenase-1 produces both protective and pathological products. Functionally, however, the overall effect of these was to drive pathological responses in the context of both vasoconstriction in vitro and the development of atherosclerosis and vascular inflammation in vivo. These data provide the first demonstration of a pathological role for the vascular cyclooxygenase-1 pathway, highlighting its potential as a therapeutic target. They also emphasize that, across biology, the role of prostanoids is not always predictable due to unique balances of context, products, and receptors.
No takes yet. Share an insight, caveat, or question.
Mitchell et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: